UBS Group
MDNA

UBS Group’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

UBS Group’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,882
Closed -$5K – 11210
2021
Q4 		$5K Buy
+2,882
New +$5.98K ﹤0.01% 9448

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's MDNA Position: Q1 2022 in Review

UBS Group sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2022, closing a stake of 2,882 shares — an estimated $5K sold.

UBS Group first reported a position in MDNA in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 20 funds tracked by Wall St. Rank hold MDNA as of Q1 2022.

  • UBS Group reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2022 after selling out during the quarter.
  • UBS Group sold 2,882 Medicenna Therapeutics Corp. Common Shares shares in Q1 2022, an estimated $5K.
  • UBS Group first reported a position in Medicenna Therapeutics Corp. Common Shares in Q4 2021 and held it in 1 quarter.
  • UBS Group's Medicenna Therapeutics Corp. Common Shares position peaked at $5K in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2022.

Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.